Tristetraprolin (TTP): Interactions with mRNA and proteins, and current thoughts on mechanisms of action

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1829, Issue 6-7, 2013, Pages 666-679

  Brooks, Seth A ^a,b   Blackshear, Perry J ^c,d  

^a VA MEDICAL CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

AU rich element; MRNA stability; MRNA translation; Post transcriptional regulation; Tristetraprolin

Indexed keywords

ADENOSINE; BINDING PROTEIN; MESSENGER RNA; TRISTETRAPROLIN; TUMOR NECROSIS FACTOR ALPHA; ZINC FINGER PROTEIN;

NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; REVIEW; TRANSCRIPTION REGULATION;

3' UNTRANSLATED REGIONS; AU RICH ELEMENTS; BASE SEQUENCE; CELL LINE; GENE EXPRESSION REGULATION; HUMANS; MOLECULAR SEQUENCE DATA; PROTEIN BIOSYNTHESIS; RNA STABILITY; RNA, MESSENGER; TRISTETRAPROLIN; TUMOR NECROSIS FACTOR-ALPHA; ZINC FINGERS;

EID: 84877793134     PISSN: 18749399     EISSN: 18764320     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2013.02.003     Document Type: Review

References (199)

1. Lopez de Silanes I., Quesada M.P., Esteller M. Aberrant regulation of messenger RNA 3'-untranslated region in human cancer. Cell. Oncol. 2007, 29:1-17.
2. Benjamin D., Moroni C. mRNA stability and cancer: an emerging link?. Expert. Opin. Biol. Ther. 2007, 7:1515-1529.
3. Hitti E., Khabar K.S. Sequence variations affecting AU-rich element function and disease. Front. Biosci. 2012, 17:1846-1860.
4. Schott J., Stoecklin G. Networks controlling mRNA decay in the immune system. Wiley Interdiscip. Rev. RNA 2010, 1:432-456.
5. Beisang D., Bohjanen P.R. Perspectives on the ARE as it turns 25years old. Wiley Interdiscip. Rev. RNA 2012, 3:719-731.
6. Bakheet T., Williams B.R., Khabar K.S. ARED 3.0: the large and diverse AU-rich transcriptome. Nucleic Acids Res. 2006, 34:D111-D114.
7. Halees A.S., El-Badrawi R., Khabar K.S. ARED Organism: expansion of ARED reveals AU-rich element cluster variations between human and mouse. Nucleic Acids Res. 2008, 36:D137-D140.
8. Mittal N., Roy N., Babu M.M., Janga S.C. Dissecting the expression dynamics of RNA-binding proteins in posttranscriptional regulatory networks. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:20300-20305.
9. Lai W.S., Stumpo D.J., Blackshear P.J. Rapid insulin-stimulated accumulation of an mRNA encoding a proline-rich protein. J. Biol. Chem. 1990, 265:16556-16563.
10. DuBois R.N., McLane M.W., Ryder K., Lau L.F., Nathans D. A growth factor-inducible nuclear protein with a novel cysteine/histidine repetitive sequence. J. Biol. Chem. 1990, 265:19185-19191.
11. Varnum B.C., Lim R.W., Sukhatme V.P., Herschman H.R. Nucleotide sequence of a cDNA encoding TIS11, a message induced in Swiss 3T3 cells by the tumor promoter tetradecanoyl phorbol acetate. Oncogene 1989, 4:119-120.
12. Ma Q., Herschman H.R. A corrected sequence for the predicted protein from the mitogen-inducible TIS11 primary response gene. Oncogene 1991, 6:1277-1278.
13. Taylor G.A. The human TTP protein: sequence, alignment with related proteins, and chromosomal localization of the mouse and human genes. Nucleic Acids Res. 1991, 19:3454.
14. Heximer S.P., Forsdyke D.R. A human putative lymphocyte G0/G1 switch gene homologous to a rodent gene encoding a zinc-binding potential transcription factor. DNA Cell Biol. 1993, 12:73-88.
15. Taylor G.A., Thompson M.J., Lai W.S., Blackshear P.J. Phosphorylation of tristetraprolin, a potential zinc finger transcription factor, by mitogen stimulation in intact cells and by mitogen-activated protein kinase in vitro. J. Biol. Chem. 1995, 270:13341-13347.
16. Taylor G.A., Thompson M.J., Lai W.S., Blackshear P.J. Mitogens stimulate the rapid nuclear to cytosolic translocation of tristetraprolin, a potential zinc-finger transcription factor. Mol. Endocrinol. (Baltimore, Md.) 1996, 10:140-146.
17. Taylor G.A., Blackshear P.J. Zinc inhibits turnover of labile mRNAs in intact cells. J. Cell. Physiol. 1995, 162:378-387.
18. Lai W.S., Thompson M.J., Taylor G.A., Liu Y., Blackshear P.J. Promoter analysis of Zfp-36, the mitogen-inducible gene encoding the zinc finger protein tristetraprolin. J. Biol. Chem. 1995, 270:25266-25272.
19. Taylor G.A., Carballo E., Lee D.M., Lai W.S., Thompson M.J., Patel D.D., Schenkman D.I., Gilkeson G.S., Broxmeyer H.E., Haynes B.F., Blackshear P.J. A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. Immunity 1996, 4:445-454.
20. Carballo E., Gilkeson G.S., Blackshear P.J. Bone marrow transplantation reproduces the tristetraprolin-deficiency syndrome in recombination activating gene-2 (-/-) mice. Evidence that monocyte/macrophage progenitors may be responsible for TNFalpha overproduction. J. Clin. Invest. 1997, 100:986-995.
21. Carballo E., Lai W.S., Blackshear P.J. Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin. Science (New York, N.Y.) 1998, 281:1001-1005.
22. Kontoyiannis D., Pasparakis M., Pizarro T.T., Cominelli F., Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 1999, 10:387-398.
23. Qiu L.Q., Stumpo D.J., Blackshear P.J. Myeloid-specific tristetraprolin deficiency in mice results in extreme lipopolysaccharide sensitivity in an otherwise minimal phenotype. J. Immunol. 2012, 188:5150-5159.
24. Kratochvill F., Machacek C., Vogl C., Ebner F., Sedlyarov V., Gruber A.R., Hartweger H., Vielnascher R., Karaghiosoff M., Rulicke T., Muller M., Hofacker I., Lang R., Kovarik P. Tristetraprolin-driven regulatory circuit controls quality and timing of mRNA decay in inflammation. Mol. Syst. Biol. 2011, 7:560.
25. Blackshear P.J., Lai W.S., Kennington E.A., Brewer G., Wilson G.M., Guan X., Zhou P. Characteristics of the interaction of a synthetic human tristetraprolin tandem zinc finger peptide with AU-rich element-containing RNA substrates. J. Biol. Chem. 2003, 278:19947-19955.
26. Worthington M.T., Pelo J.W., Sachedina M.A., Applegate J.L., Arseneau K.O., Pizarro T.T. RNA binding properties of the AU-rich element-binding recombinant Nup475/TIS11/tristetraprolin protein. J. Biol. Chem. 2002, 277:48558-48564.
27. Lai W.S., Carballo E., Thorn J.M., Kennington E.A., Blackshear P.J. Interactions of CCCH zinc finger proteins with mRNA. Binding of tristetraprolin-related zinc finger proteins to Au-rich elements and destabilization of mRNA. J. Biol. Chem. 2000, 275:17827-17837.
28. Brewer B.Y., Malicka J., Blackshear P.J., Wilson G.M. RNA sequence elements required for high affinity binding by the zinc finger domain of tristetraprolin: conformational changes coupled to the bipartite nature of Au-rich MRNA-destabilizing motifs. J. Biol. Chem. 2004, 279:27870-27877.
29. Hudson B.P., Martinez-Yamout M.A., Dyson H.J., Wright P.E. Recognition of the mRNA AU-rich element by the zinc finger domain of TIS11d. Nat. Struct. Mol. Biol. 2004, 11:257-264.
30. Carrick D.M., Lai W.S., Blackshear P.J. The tandem CCCH zinc finger protein tristetraprolin and its relevance to cytokine mRNA turnover and arthritis. Arthritis Res. Ther. 2004, 6:248-264.
31. Blackshear P.J., Phillips R.S., Ghosh S., Ramos S.B., Richfield E.K., Lai W.S. Zfp36l3, a rodent X chromosome gene encoding a placenta-specific member of the Tristetraprolin family of CCCH tandem zinc finger proteins. Biol. Reprod. 2005, 73:297-307.
32. De J., Lai W.S., Thorn J.M., Goldsworthy S.M., Liu X., Blackwell T.K., Blackshear P.J. Identification of four CCCH zinc finger proteins in Xenopus, including a novel vertebrate protein with four zinc fingers and severely restricted expression. Gene 1999, 228:133-145.
33. Belloc E., Mendez R. A deadenylation negative feedback mechanism governs meiotic metaphase arrest. Nature 2008, 452:1017-1021.
34. Kaymak E., Wee L.M., Ryder S.P. Structure and function of nematode RNA-binding proteins. Curr. Opin. Struct. Biol. 2010, 20:305-312.
35. Carballo E., Blackshear P.J. Roles of tumor necrosis factor-alpha receptor subtypes in the pathogenesis of the tristetraprolin-deficiency syndrome. Blood 2001, 98:2389-2395.
36. Lai W.S., Parker J.S., Grissom S.F., Stumpo D.J., Blackshear P.J. Novel mRNA targets for tristetraprolin (TTP) identified by global analysis of stabilized transcripts in TTP-deficient fibroblasts. Mol. Cell. Biol. 2006, 26:9196-9208.
37. Shaw G., Kamen R. A conserved AU sequence from the 3' untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 1986, 46:659-667.
38. Carballo E., Lai W.S., Blackshear P.J. Evidence that tristetraprolin is a physiological regulator of granulocyte-macrophage colony-stimulating factor messenger RNA deadenylation and stability. Blood 2000, 95:1891-1899.
39. Lai W.S., Carballo E., Strum J.R., Kennington E.A., Phillips R.S., Blackshear P.J. Evidence that tristetraprolin binds to AU-rich elements and promotes the deadenylation and destabilization of tumor necrosis factor alpha mRNA. Mol. Cell. Biol. 1999, 19:4311-4323.
40. Lai W.S., Kennington E.A., Blackshear P.J. Tristetraprolin and its family members can promote the cell-free deadenylation of AU-rich element-containing mRNAs by poly(A) ribonuclease. Mol. Cell. Biol. 2003, 23:3798-3812.
41. Stoecklin G., Ming X.F., Looser R., Moroni C. Somatic mRNA turnover mutants implicate tristetraprolin in the interleukin-3 mRNA degradation pathway. Mol. Cell. Biol. 2000, 20:3753-3763.
42. Ming X.F., Stoecklin G., Lu M., Looser R., Moroni C. Parallel and independent regulation of interleukin-3 mRNA turnover by phosphatidylinositol 3-kinase and p38 mitogen-activated protein kinase. Mol. Cell. Biol. 2001, 21:5778-5789.
43. Raghavan A., Robison R.L., McNabb J., Miller C.R., Williams D.A., Bohjanen P.R. HuA and tristetraprolin are induced following T cell activation and display distinct but overlapping RNA binding specificities. J. Biol. Chem. 2001, 276:47958-47965.
44. Zhu W., Brauchle M.A., Di Padova F., Gram H., New L., Ono K., Downey J.S., Han J. Gene suppression by tristetraprolin and release by the p38 pathway. Am. J. Physiol. Lung Cell. Mol. Physiol. 2001, 281:L499-L508.
45. Jing Q., Huang S., Guth S., Zarubin T., Motoyama A., Chen J., Di Padova F., Lin S.C., Gram H., Han J. Involvement of microRNA in AU-rich element-mediated mRNA instability. Cell 2005, 120:623-634.
46. Mols J., van den Berg A., Otsuka M., Zheng M., Chen J., Han J. TNF-alpha stimulation inhibits siRNA-mediated RNA interference through a mechanism involving poly-(A) tail stabilization. Biochim. Biophys. Acta 2008, 1779:712-719.
47. Helfer S., Schott J., Stoecklin G., Forstemann K. AU-rich element-mediated mRNA decay can occur independently of the miRNA machinery in mouse embryonic fibroblasts and Drosophila S2-cells. PLoS One 2012, 7:e28907.
48. Liang J., Lei T., Song Y., Yanes N., Qi Y., Fu M. RNA-destabilizing factor tristetraprolin negatively regulates NF-kappaB signaling. J. Biol. Chem. 2009, 284:29383-29390.
49. Schichl Y.M., Resch U., Hofer-Warbinek R., de Martin R. Tristetraprolin impairs NF-kappaB/p65 nuclear translocation. J. Biol. Chem. 2009, 284:29571-29581.
50. Ness G.C., Edelman J.L., Brooks P.A. Involvement of tristetraprolin in transcriptional activation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase by insulin. Biochem. Biophys. Res. Commun. 2012, 420:178-182.
51. Maeda M., Sawa H., Tobiume M., Tokunaga K., Hasegawa H., Ichinohe T., Sata T., Moriyama M., Hall W.W., Kurata T., Takahashi H. Tristetraprolin inhibits HIV-1 production by binding to genomic RNA. Microbes Infect. 2006, 8:2647-2656.
52. Fechir M., Linker K., Pautz A., Hubrich T., Forstermann U., Rodriguez-Pascual F., Kleinert H. Tristetraprolin regulates the expression of the human inducible nitric-oxide synthase gene. Mol. Pharmacol. 2005, 67:2148-2161.
53. Linker K., Pautz A., Fechir M., Hubrich T., Greeve J., Kleinert H. Involvement of KSRP in the post-transcriptional regulation of human iNOS expression-complex interplay of KSRP with TTP and HuR. Nucleic Acids Res. 2005, 33:4813-4827.
54. Cao H., Deterding L.J., Blackshear P.J. Phosphorylation site analysis of the anti-inflammatory and mRNA-destabilizing protein tristetraprolin. Expert Rev. Proteomics 2007, 4:711-726.
55. Pfeiffer J.R., Brooks S.A. Cullin 4B is recruited to tristetraprolin-containing messenger ribonucleoproteins and regulates TNF-alpha mRNA polysome loading. J. Immunol. 2012, 188:1828-1839.
56. Hitti E., Iakovleva T., Brook M., Deppenmeier S., Gruber A.D., Radzioch D., Clark A.R., Blackshear P.J., Kotlyarov A., Gaestel M. Mitogen-activated protein kinase-activated protein kinase 2 regulates tumor necrosis factor mRNA stability and translation mainly by altering tristetraprolin expression, stability, and binding to adenine/uridine-rich element. Mol. Cell. Biol. 2006, 26:2399-2407.
57. Deleault K.M., Skinner S.J., Brooks S.A. Tristetraprolin regulates TNF TNF-alpha mRNA stability via a proteasome dependent mechanism involving the combined action of the ERK and p38 pathways. Mol. Immunol. 2008, 45:13-24.
58. Cao H., Dzineku F., Blackshear P.J. Expression and purification of recombinant tristetraprolin that can bind to tumor necrosis factor-alpha mRNA and serve as a substrate for mitogen-activated protein kinases. Arch. Biochem. Biophys. 2003, 412:106-120.
59. Carballo E., Cao H., Lai W.S., Kennington E.A., Campbell D., Blackshear P.J. Decreased sensitivity of tristetraprolin-deficient cells to p38 inhibitors suggests the involvement of tristetraprolin in the p38 signaling pathway. J. Biol. Chem. 2001, 276:42580-42587.
60. Chrestensen C.A., Schroeder M.J., Shabanowitz J., Hunt D.F., Pelo J.W., Worthington M.T., Sturgill T.W. MAPKAP kinase 2 phosphorylates tristetraprolin on in vivo sites including Ser178, a site required for 14-3-3 binding. J. Biol. Chem. 2004, 279:10176-10184.
61. Mahtani K.R., Brook M., Dean J.L., Sully G., Saklatvala J., Clark A.R. Mitogen-activated protein kinase p38 controls the expression and posttranslational modification of tristetraprolin, a regulator of tumor necrosis factor alpha mRNA stability. Mol. Cell. Biol. 2001, 21:6461-6469.
62. Clark A., Dean J., Tudor C., Saklatvala J. Post-transcriptional gene regulation by MAP kinases via AU-rich elements. Front. Biosci. 2009, 14:847-871.
63. Sun L., Stoecklin G., Van Way S., Hinkovska-Galcheva V., Guo R.F., Anderson P., Shanley T.P. Tristetraprolin (TTP)-14-3-3 complex formation protects TTP from dephosphorylation by protein phosphatase 2a and stabilizes tumor necrosis factor-alpha mRNA. J. Biol. Chem. 2007, 282:3766-3777.
64. Lee W.H., Lee H.H., Vo M.T., Kim H.J., Ko M.S., Im Y.C., Min Y.J., Lee B.J., Cho W.J., Park J.W. Casein kinase 2 regulates the mRNA-destabilizing activity of tristetraprolin. J. Biol. Chem. 2011, 286:21577-21587.
65. Rigby W.F., Roy K., Collins J., Rigby S., Connolly J.E., Bloch D.B., Brooks S.A. Structure/function analysis of tristetraprolin (TTP): p38 stress-activated protein kinase and lipopolysaccharide stimulation do not alter TTP function. J. Immunol. 2005, 174:7883-7893.
66. Stoecklin G., Stubbs T., Kedersha N., Wax S., Rigby W.F., Blackwell T.K., Anderson P. MK2-induced tristetraprolin:14-3-3 complexes prevent stress granule association and ARE-mRNA decay. EMBO J. 2004, 23:1313-1324.
67. Cao H. Expression, purification, and biochemical characterization of the antiinflammatory tristetraprolin: a zinc-dependent mRNA binding protein affected by posttranslational modifications. Biochemistry 2004, 43:13724-13738.
68. Pfeiffer J.R., McAvoy B.L., Fecteau R.E., Deleault K.M., Brooks S.A. CARHSP1 is required for effective tumor necrosis factor alpha mRNA stabilization and localizes to processing bodies and exosomes. Mol. Cell. Biol. 2011, 31:277-286.
69. Clement S.L., Scheckel C., Stoecklin G., Lykke-Andersen J. Phosphorylation of tristetraprolin by MK2 impairs AU-rich element mRNA decay by preventing deadenylase recruitment. Mol. Cell. Biol. 2011, 31:256-266.
70. Marchese F.P., Aubareda A., Tudor C., Saklatvala J., Clark A.R., Dean J.L. MAPKAP kinase 2 blocks tristetraprolin-directed mRNA decay by inhibiting CAF1 deadenylase recruitment. J. Biol. Chem. 2010, 285:27590-27600.
71. Schmidlin M., Lu M., Leuenberger S.A., Stoecklin G., Mallaun M., Gross B., Gherzi R., Hess D., Hemmings B.A., Moroni C. The ARE-dependent mRNA-destabilizing activity of BRF1 is regulated by protein kinase B. EMBO J. 2004, 23:4760-4769.
72. Maitra S., Chou C.F., Luber C.A., Lee K.Y., Mann M., Chen C.Y. The AU-rich element mRNA decay-promoting activity of BRF1 is regulated by mitogen-activated protein kinase-activated protein kinase 2. RNA 2008, 14:950-959.
73. Marderosian M., Sharma A., Funk A.P., Vartanian R., Masri J., Jo O.D., Gera J.F. Tristetraprolin regulates Cyclin D1 and c-Myc mRNA stability in response to rapamycin in an Akt-dependent manner via p38 MAPK signaling. Oncogene 2006, 25:6277-6290.
74. Benjamin D., Schmidlin M., Min L., Gross B., Moroni C. BRF1 protein turnover and mRNA decay activity are regulated by protein kinase B at the same phosphorylation sites. Mol. Cell. Biol. 2006, 26:9497-9507.
75. Essafi-Benkhadir K., Pouyssegur J., Pages G. Implication of the ERK pathway on the post-transcriptional regulation of VEGF mRNA stability. Methods Mol. Biol. 2010, 661:451-469.
76. Brook M., Tchen C.R., Santalucia T., McIlrath J., Arthur J.S., Saklatvala J., Clark A.R. Posttranslational regulation of tristetraprolin subcellular localization and protein stability by p38 mitogen-activated protein kinase and extracellular signal-regulated kinase pathways. Mol. Cell. Biol. 2006, 26:2408-2418.
77. Brooks S.A., Connolly J.E., Rigby W.F. The role of mRNA turnover in the regulation of tristetraprolin expression: evidence for an extracellular signal-regulated kinase-specific, AU-rich element-dependent, autoregulatory pathway. J. Immunol. 2004, 172:7263-7271.
78. Tchen C.R., Brook M., Saklatvala J., Clark A.R. The stability of tristetraprolin mRNA is regulated by mitogen-activated protein kinase p38 and by tristetraprolin itself. J. Biol. Chem. 2004, 279:32393-32400.
79. Stoecklin G., Tenenbaum S.A., Mayo T., Chittur S.V., George A.D., Baroni T.E., Blackshear P.J., Anderson P. Genome-wide analysis identifies interleukin-10 mRNA as target of tristetraprolin. J. Biol. Chem. 2008, 283:11689-11699.
80. Silva A.L., Romao L. The mammalian nonsense-mediated mRNA decay pathway: to decay or not to decay! Which players make the decision?. FEBS Lett. 2009, 583:499-505.
81. Neu-Yilik G., Kulozik A.E. NMD: multitasking between mRNA surveillance and modulation of gene expression. Adv. Genet. 2008, 62:185-243.
82. van Hoof A., Frischmeyer P.A., Dietz H.C., Parker R. Exosome-mediated recognition and degradation of mRNAs lacking a termination codon. Science 2002, 295:2262-2264.
83. Frischmeyer P.A., van Hoof A., O'Donnell K., Guerrerio A.L., Parker R., Dietz H.C. An mRNA surveillance mechanism that eliminates transcripts lacking termination codons. Science 2002, 295:2258-2261.
84. Harigaya Y., Parker R. No-go decay: a quality control mechanism for RNA in translation. Wiley Interdiscip. Rev. RNA 2010, 1:132-141.
85. Moore M.J. From birth to death: the complex lives of eukaryotic mRNAs. Science 2005, 309:1514-1518.
86. Schwede A., Ellis L., Luther J., Carrington M., Stoecklin G., Clayton C. A role for Caf1 in mRNA deadenylation and decay in trypanosomes and human cells. Nucleic Acids Res. 2008, 36:3374-3388.
87. Yamashita A., Chang T.C., Yamashita Y., Zhu W., Zhong Z., Chen C.Y., Shyu A.B. Concerted action of poly(A) nucleases and decapping enzyme in mammalian mRNA turnover. Nat. Struct. Mol. Biol. 2005, 12:1054-1063.
88. Parker R., Song H. The enzymes and control of eukaryotic mRNA turnover. Nat. Struct. Mol. Biol. 2004, 11:121-127.
89. Eulalio A., Behm-Ansmant I., Izaurralde E. P bodies: at the crossroads of post-transcriptional pathways. Nat. Rev. Mol. Cell Biol. 2007, 8:9-22.
90. Garneau N.L., Wilusz J., Wilusz C.J. The highways and byways of mRNA decay. Nat. Rev. Mol. Cell Biol. 2007, 8:113-126.
91. Parker R., Sheth U. P bodies and the control of mRNA translation and degradation. Mol. Cell 2007, 25:635-646.
92. Franks T.M., Lykke-Andersen J. The control of mRNA decapping and P-body formation. Mol. Cell 2008, 32:605-615.
93. Anderson P., Kedersha N. RNA granules: post-transcriptional and epigenetic modulators of gene expression. Nat. Rev. Mol. Cell Biol. 2009, 10:430-436.
94. Eulalio A., Behm-Ansmant I., Schweizer D., Izaurralde E. P-body formation is a consequence, not the cause, of RNA-mediated gene silencing. Mol. Cell. Biol. 2007, 27:3970-3981.
95. Franks T.M., Lykke-Andersen J. TTP and BRF proteins nucleate processing body formation to silence mRNAs with AU-rich elements. Genes Dev. 2007, 21:719-735.
96. Cougot N., Babajko S., Seraphin B. Cytoplasmic foci are sites of mRNA decay in human cells. J. Cell Biol. 2004, 165:31-40.
97. Teixeira D., Sheth U., Valencia-Sanchez M.A., Brengues M., Parker R. Processing bodies require RNA for assembly and contain nontranslating mRNAs. RNA 2005, 11:371-382.
98. Dember L.M., Kim N.D., Liu K.Q., Anderson P. Individual RNA recognition motifs of TIA-1 and TIAR have different RNA binding specificities. J. Biol. Chem. 1996, 271:2783-2788.
99. Gueydan C., Droogmans L., Chalon P., Huez G., Caput D., Kruys V. Identification of TIAR as a protein binding to the translational regulatory AU-rich element of tumor necrosis factor alpha mRNA. J. Biol. Chem. 1999, 274:2322-2326.
100. Piecyk M., Wax S., Beck A.R., Kedersha N., Gupta M., Maritim B., Chen S., Gueydan C., Kruys V., Streuli M., Anderson P. TIA-1 is a translational silencer that selectively regulates the expression of TNF-alpha. EMBO J. 2000, 19:4154-4163.
101. Lopez de Silanes I., Galban S., Martindale J.L., Yang X., Mazan-Mamczarz K., Indig F.E., Falco G., Zhan M., Gorospe M. Identification and functional outcome of mRNAs associated with RNA-binding protein TIA-1. Mol. Cell. Biol. 2005, 25:9520-9531.
102. Mazan-Mamczarz K., Lal A., Martindale J.L., Kawai T., Gorospe M. Translational repression by RNA-binding protein TIAR. Mol. Cell. Biol. 2006, 26:2716-2727.
103. Kedersha N., Stoecklin G., Ayodele M., Yacono P., Lykke-Andersen J., Fritzler M.J., Scheuner D., Kaufman R.J., Golan D.E., Anderson P. Stress granules and processing bodies are dynamically linked sites of mRNP remodeling. J. Cell Biol. 2005, 169:871-884.
104. Lykke-Andersen S., Brodersen D.E., Jensen T.H. Origins and activities of the eukaryotic exosome. J. Cell Sci. 2009, 122:1487-1494.
105. Ibrahim H., Wilusz J., Wilusz C.J. RNA recognition by 3'-to-5' exonucleases: the substrate perspective. Biochim. Biophys. Acta 2008, 1779:256-265.
106. Brooks S.A. Functional interactions between mRNA turnover and surveillance and the ubiquitin proteasome system, WIREs RNA 1 2010, (epub May 14, 2010).
107. Stoecklin G., Mayo T., Anderson P. ARE-mRNA degradation requires the 5'-3' decay pathway. EMBO Rep. 2006, 7:72-77.
108. Chen C.Y., Gherzi R., Ong S.E., Chan E.L., Raijmakers R., Pruijn G.J., Stoecklin G., Moroni C., Mann M., Karin M. AU binding proteins recruit the exosome to degrade ARE-containing mRNAs. Cell 2001, 107:451-464.
109. Kedersha N., Anderson P. Stress granules: sites of mRNA triage that regulate mRNA stability and translatability. Biochem. Soc. Trans. 2002, 30:963-969.
110. Phillips K., Kedersha N., Shen L., Blackshear P.J., Anderson P. Arthritis suppressor genes TIA-1 and TTP dampen the expression of tumor necrosis factor alpha, cyclooxygenase 2, and inflammatory arthritis. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:2011-2016.
111. Buchan J.R., Parker R. Eukaryotic stress granules: the ins and outs of translation. Mol. Cell 2009, 36:932-941.
112. Anderson P., Kedersha N. Stressful initiations. J. Cell Sci. 2002, 115:3227-3234.
113. Sandler H., Kreth J., Timmers H.T., Stoecklin G. Not1 mediates recruitment of the deadenylase Caf1 to mRNAs targeted for degradation by tristetraprolin. Nucleic Acids Res. 2011, 39:4373-4386.
114. Lykke-Andersen J., Wagner E. Recruitment and activation of mRNA decay enzymes by two ARE-mediated decay activation domains in the proteins TTP and BRF-1. Genes Dev. 2005, 19:351-361.
115. Sonenberg N., Hinnebusch A.G. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 2009, 136:731-745.
116. Kotlyarov A., Gaestel M. Is MK2 (mitogen-activated protein kinase-activated protein kinase 2) the key for understanding post-transcriptional regulation of gene expression?. Biochem. Soc. Trans. 2002, 30:959-963.
117. Neininger A., Kontoyiannis D., Kotlyarov A., Winzen R., Eckert R., Volk H.D., Holtmann H., Kollias G., Gaestel M. MK2 targets AU-rich elements and regulates biosynthesis of tumor necrosis factor and interleukin-6 independently at different post-transcriptional levels. J. Biol. Chem. 2002, 277:3065-3068.
118. Ronkina N., Kotlyarov A., Dittrich-Breiholz O., Kracht M., Hitti E., Milarski K., Askew R., Marusic S., Lin L.L., Gaestel M., Telliez J.B. The mitogen-activated protein kinase (MAPK)-activated protein kinases MK2 and MK3 cooperate in stimulation of tumor necrosis factor biosynthesis and stabilization of p38 MAPK. Mol. Cell. Biol. 2007, 27:170-181.
119. Qi M.Y., Wang Z.Z., Zhang Z., Shao Q., Zeng A., Li X.Q., Li W.Q., Wang C., Tian F.J., Li Q., Zou J., Qin Y.W., Brewer G., Huang S., Jing Q. AU-rich-element-dependent translation repression requires the cooperation of tristetraprolin and RCK/P54. Mol. Cell. Biol. 2012, 32:913-928.
120. Fenger-Gron M., Fillman C., Norrild B., Lykke-Andersen J. Multiple processing body factors and the ARE binding protein TTP activate mRNA decapping. Mol. Cell 2005, 20:905-915.
121. Holetz F.B., Correa A., Avila A.R., Nakamura C.V., Krieger M.A., Goldenberg S. Evidence of P-body-like structures in Trypanosoma cruzi. Biochem. Biophys. Res. Commun. 2007, 356:1062-1067.
122. Coller J., Parker R. General translational repression by activators of mRNA decapping. Cell 2005, 122:875-886.
123. Schwartz D.C., Parker R. mRNA decapping in yeast requires dissociation of the cap binding protein, eukaryotic translation initiation factor 4E. Mol. Cell. Biol. 2000, 20:7933-7942.
124. Schwartz D.C., Parker R. Mutations in translation initiation factors lead to increased rates of deadenylation and decapping of mRNAs in Saccharomyces cerevisiae. Mol. Cell. Biol. 1999, 19:5247-5256.
125. Sheth U., Parker R. Decapping and decay of messenger RNA occur in cytoplasmic processing bodies. Science 2003, 300:805-808.
126. Yamasaki S., Stoecklin G., Kedersha N., Simarro M., Anderson P. T-cell intracellular antigen-1 (TIA-1)-induced translational silencing promotes the decay of selected mRNAs. J. Biol. Chem. 2007, 282:30070-30077.
127. Tiedje C., Ronkina N., Tehrani M., Dhamija S., Laass K., Holtmann H., Kotlyarov A., Gaestel M. The p38/MK2-driven exchange between tristetraprolin and HuR regulates AU-rich element-dependent translation. PLoS Genet. 2012, 8:e1002977.
128. Stoecklin G., Gross B., Ming X.F., Moroni C. A novel mechanism of tumor suppression by destabilizing AU-rich growth factor mRNA. Oncogene 2003, 22:3554-3561.
129. Holmes B., Artinian N., Anderson L., Martin J., Masri J., Cloninger C., Bernath A., Bashir T., Benavides-Serrato A., Gera J. Protor-2 interacts with tristetraprolin to regulate mRNA stability during stress. Cell. Signal. 2012, 24:309-315.
130. Boutaud O., Dixon D.A., Oates J.A., Sawaoka H. Tristetraprolin binds to the COX-2 mRNA 3' untranslated region in cancer cells. Adv. Exp. Med. Biol. 2003, 525:157-160.
131. Sawaoka H., Dixon D.A., Oates J.A., Boutaud O. Tristetraprolin binds to the 3'-untranslated region of cyclooxygenase-2 mRNA. A polyadenylation variant in a cancer cell line lacks the binding site. J. Biol. Chem. 2003, 278:13928-13935.
132. Sully G., Dean J.L., Wait R., Rawlinson L., Santalucia T., Saklatvala J., Clark A.R. Structural and functional dissection of a conserved destabilizing element of cyclo-oxygenase-2 mRNA: evidence against the involvement of AUF-1 [AU-rich element/poly(U)-binding/degradation factor-1], AUF-2, tristetraprolin, HuR (Hu antigen R) or FBP1 (far-upstream-sequence-element-binding protein 1). Biochem. J. 2004, 377:629-639.
133. Lin N.Y., Lin C.T., Chang C.J. Modulation of immediate early gene expression by tristetraprolin in the differentiation of 3T3-L1 cells. Biochem. Biophys. Res. Commun. 2008, 365:69-74.
134. Young L.E., Sanduja S., Bemis-Standoli K., Pena E.A., Price R.L., Dixon D.A. The mRNA binding proteins HuR and tristetraprolin regulate cyclooxygenase 2 expression during colon carcinogenesis. Gastroenterology 2009, 136:1669-1679.
135. Al-Souhibani N., Al-Ahmadi W., Hesketh J.E., Blackshear P.J., Khabar K.S. The RNA-binding zinc-finger protein tristetraprolin regulates AU-rich mRNAs involved in breast cancer-related processes. Oncogene 2010, 29:4205-4215.
136. Cha H.J., Lee H.H., Chae S.W., Cho W.J., Kim Y.M., Choi H.J., Choi D.H., Jung S.W., Min Y.J., Lee B.J., Park S.E., Park J.W. Tristetraprolin downregulates the expression of both VEGF and COX-2 in human colon cancer. Hepatogastroenterology 2011, 58:790-795.
137. Briata P., Ilengo C., Corte G., Moroni C., Rosenfeld M.G., Chen C.Y., Gherzi R. The Wnt/beta-catenin-->Pitx2 pathway controls the turnover of Pitx2 and other unstable mRNAs. Mol. cell 2003, 12:1201-1211.
138. Yu H., Stasinopoulos S., Leedman P., Medcalf R.L. Inherent instability of plasminogen activator inhibitor type 2 mRNA is regulated by tristetraprolin. J. Biol. Chem. 2003, 278:13912-13918.
139. Ogilvie R.L., Abelson M., Hau H.H., Vlasova I., Blackshear P.J., Bohjanen P.R. Tristetraprolin down-regulates IL-2 gene expression through AU-rich element-mediated mRNA decay. J. Immunol. 2005, 174:953-961.
140. Chen Y.L., Huang Y.L., Lin N.Y., Chen H.C., Chiu W.C., Chang C.J. Differential regulation of ARE-mediated TNFalpha and IL-1beta mRNA stability by lipopolysaccharide in RAW264.7 cells. Biochem. Biophys. Res. Commun. 2006, 346:160-168.
141. Jalonen U., Nieminen R., Vuolteenaho K., Kankaanranta H., Moilanen E. Down-regulation of tristetraprolin expression results in enhanced IL-12 and MIP-2 production and reduced MIP-3alpha synthesis in activated macrophages. Mediators Inflamm. 2006, 2006:40691.
142. Sauer I., Schaljo B., Vogl C., Gattermeier I., Kolbe T., Muller M., Blackshear P.J., Kovarik P. Interferons limit inflammatory responses by induction of tristetraprolin. Blood 2006, 107:4790-4797.
143. Patil C.S., Liu M., Zhao W., Coatney D.D., Li F., VanTubergen E.A., D'Silva N.J., Kirkwood K.L. Targeting mRNA stability arrests inflammatory bone loss. Mol. Ther. 2008, 16:1657-1664.
144. Van Tubergen E., Vander Broek R., Lee J., Wolf G., Carey T., Bradford C., Prince M., Kirkwood K.L., D'Silva N.J. Tristetraprolin regulates interleukin-6, which is correlated with tumor progression in patients with head and neck squamous cell carcinoma. Cancer 2011, 117:2677-2689.
145. Zhao W., Liu M., D'Silva N.J., Kirkwood K.L. Tristetraprolin regulates interleukin-6 expression through p38 MAPK-dependent affinity changes with mRNA 3' untranslated region. J. Interferon Cytokine Res. 2011, 31:629-637.
146. Brahma P.K., Zhang H., Murray B.S., Shu F.J., Sidell N., Seli E., Kallen C.B. The mRNA-binding protein Zfp36 is upregulated by beta-adrenergic stimulation and represses IL-6 production in 3T3-L1 adipocytes. Obesity (Silver Spring) 2012, 20:40-47.
147. Horner T.J., Lai W.S., Stumpo D.J., Blackshear P.J. Stimulation of polo-like kinase 3 mRNA decay by tristetraprolin. Mol. Cell. Biol. 2009, 29:1999-2010.
148. Sohn B.H., Park I.Y., Lee J.J., Yang S.J., Jang Y.J., Park K.C., Kim D.J., Lee D.C., Sohn H.A., Kim T.W., Yoo H.S., Choi J.Y., Bae Y.S., Yeom Y.I. Functional switching of TGF-beta1 signaling in liver cancer via epigenetic modulation of a single CpG site in TTP promoter. Gastroenterology 2010, 138:1898-1908.
149. Kang J.-G., Amar M.J., Remaley A.T., Kwon J., Blackshear P.J., Wang P.-y., Hwang P.M. Zinc finger protein tristetraprolin interacts with CCL3 mRNA and regulates tissue inflammation. J. Immunol. 2011, 187:2696-2701.
150. Essafi-Benkhadir K., Onesto C., Stebe E., Moroni C., Pages G. Tristetraprolin inhibits Ras-dependent tumor vascularization by inducing vascular endothelial growth factor mRNA degradation. Mol. Biol. Cell 2007, 18:4648-4658.
151. Suswam E., Li Y., Zhang X., Gillespie G.Y., Li X., Shacka J.J., Lu L., Zheng L., King P.H. Tristetraprolin down-regulates interleukin-8 and vascular endothelial growth factor in malignant glioma cells. Cancer Res. 2008, 68:674-682.
152. Lee H.H., Son Y.J., Lee W.H., Park Y.W., Chae S.W., Cho W.J., Kim Y.M., Choi H.J., Choi D.H., Jung S.W., Min Y.J., Park S.E., Lee B.J., Cha H.J., Park J.W. Tristetraprolin regulates expression of VEGF and tumorigenesis in human colon cancer. Int. J. Cancer 2010, 126:1817-1827.
153. Frasca D., Landin A.M., Alvarez J.P., Blackshear P.J., Riley R.L., Blomberg B.B. Tristetraprolin, a negative regulator of mRNA stability, is increased in old B cells and is involved in the degradation of E47 mRNA. J. Immunol. 2007, 179:918-927.
154. Winzen R., Thakur B.K., Dittrich-Breiholz O., Shah M., Redich N., Dhamija S., Kracht M., Holtmann H. Functional analysis of KSRP interaction with the AU-rich element of interleukin-8 and identification of inflammatory mRNA targets. Mol. Cell. Biol. 2007, 27:8388-8400.
155. Balakathiresan N.S., Bhattacharyya S., Gutti U., Long R.P., Jozwik C., Huang W., Srivastava M., Pollard H.B., Biswas R. Tristetraprolin regulates IL-8 mRNA stability in cystic fibrosis lung epithelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2009, 296:L1012-L1018.
156. Bhattacharyya S., Gutti U., Mercado J., Moore C., Pollard H.B., Biswas R. MAPK signaling pathways regulate IL-8 mRNA stability and IL-8 protein expression in cystic fibrosis lung epithelial cell lines. Am. J. Physiol. Lung Cell. Mol. Physiol. 2011, 300:L81-L87.
157. Bourcier C., Griseri P., Grepin R., Bertolotto C., Mazure N., Pages G. Constitutive ERK activity induces downregulation of tristetraprolin, a major protein controlling interleukin8/CXCL8 mRNA stability in melanoma cells. Am. J. Physiol. Cell Physiol. 2011, 301:C609-C618.
158. Al Ghouleh I., Magder S. NADPH oxidase-derived superoxide destabilizes lipopolysaccharide-induced interleukin 8 mRNA via p38, extracellular signal-regulated kinase mitogen-activated protein kinase, and the destabilizing factor tristetraprolin. Shock 2012, 37:433-440.
159. Galbiati V., Carne A., Mitjans M., Galli C.L., Marinovich M., Corsini E. Isoeugenol destabilizes IL-8 mRNA expression in THP-1 cells through induction of the negative regulator of mRNA stability tristetraprolin. Arch. Toxicol. 2012, 86:239-248.
160. Datta S., Biswas R., Novotny M., Pavicic P.G., Herjan T., Mandal P., Hamilton T.A. Tristetraprolin regulates CXCL1 (KC) mRNA stability. J. Immunol. 2008, 180:2545-2552.
161. Tudor C., Marchese F.P., Hitti E., Aubareda A., Rawlinson L., Gaestel M., Blackshear P.J., Clark A.R., Saklatvala J., Dean J.L. The p38 MAPK pathway inhibits tristetraprolin-directed decay of interleukin-10 and pro-inflammatory mediator mRNAs in murine macrophages. FEBS Lett. 2009, 583:1933-1938.
162. Gaba A., Grivennikov S.I., Do M.V., Stumpo D.J., Blackshear P.J., Karin M. Cutting edge: IL-10-mediated tristetraprolin induction is part of a feedback loop that controls macrophage STAT3 activation and cytokine production. J. Immunol. Sep 1 2012, 189(5):2089-2093.
163. Sze K.L., Lui W.Y., Lee W.M. Post-transcriptional regulation of CLMP mRNA is controlled by tristetraprolin in response to TNFalpha via c-Jun N-terminal kinase signalling. Biochem. J. 2008, 410:575-583.
164. Ogilvie R.L., Sternjohn J.R., Rattenbacher B., Vlasova I.A., Williams D.A., Hau H.H., Blackshear P.J., Bohjanen P.R. Tristetraprolin mediates interferon-gamma mRNA decay. J. Biol. Chem. 2009, 284:11216-11223.
165. Sanduja S., Kaza V., Dixon D.A. The mRNA decay factor tristetraprolin (TTP) induces senescence in human papillomavirus-transformed cervical cancer cells by targeting E6-AP ubiquitin ligase. Aging (Albany NY) 2009, 1:803-817.
166. Schaljo B., Kratochvill F., Gratz N., Sadzak I., Sauer I., Hammer M., Vogl C., Strobl B., Muller M., Blackshear P.J., Poli V., Lang R., Murray P.J., Kovarik P. Tristetraprolin is required for full anti-inflammatory response of murine macrophages to IL-10. J. Immunol. 2009, 183:1197-1206.
167. Tsai C.S., Chen D.L., Lin S.J., Tsai J.C., Lin T.C., Lin C.Y., Chen Y.H., Huang G.S., Tsai H.Y., Lin F.Y., Li C.Y. TNF-alpha inhibits toll-like receptor 4 expression on monocytic cells via tristetraprolin during cardiopulmonary bypass. Shock 2009, 32:40-48.
168. Kim C.W., Kim H.K., Vo M.T., Lee H.H., Kim H.J., Min Y.J., Cho W.J., Park J.W. Tristetraprolin controls the stability of cIAP2 mRNA through binding to the 3'UTR of cIAP2 mRNA. Biochem. Biophys. Res. Commun. 2010, 400:46-52.
169. Kim T.W., Yim S., Choi B.J., Jang Y., Lee J.J., Sohn B.H., Yoo H.S., Yeom Y.I., Park K.C. Tristetraprolin regulates the stability of HIF-1alpha mRNA during prolonged hypoxia. Biochem. Biophys. Res. Commun. 2010, 391:963-968.
170. Chamboredon S., Ciais D., Desroches-Castan A., Savi P., Bono F., Feige J.J., Cherradi N. Hypoxia-inducible factor-1alpha mRNA: a new target for destabilization by tristetraprolin in endothelial cells. Mol. Biol. Cell 2011, 22:3366-3378.
171. Lee H.H., Vo M.T., Kim H.J., Lee U.H., Kim C.W., Kim H.K., Ko M.S., Lee W.H., Cha S.J., Min Y.J., Choi D.H., Suh H.S., Lee B.J., Park J.W., Cho W.J. Stability of the LATS2 tumor suppressor gene is regulated by tristetraprolin. J. Biol. Chem. 2010, 285:17329-17337.
172. Bermudez O., Jouandin P., Rottier J., Bourcier C., Pages G., Gimond C. Post-transcriptional regulation of the DUSP6/MKP-3 phosphatase by MEK/ERK signaling and hypoxia. J. Cell. Physiol. 2011, 226:276-284.
173. Chen F., Shyu A.B., Shneider B.L. Hu antigen R and tristetraprolin: counter-regulators of rat apical sodium-dependent bile acid transporter by way of effects on messenger RNA stability. Hepatology 2011, 54:1371-1378.
174. Lin F.Y., Tsai Y.T., Lee C.Y., Lin C.Y., Lin Y.W., Li C.Y., Shih C.M., Huang C.Y., Chang N.C., Tsai J.C., Chen T.L., Tsai C.S. TNF-alpha-decreased thrombomodulin expression in monocytes is inhibited by propofol through regulation of tristetraprolin and human antigen R activities. Shock 2011, 36:279-288.
175. Qian X., Ning H., Zhang J., Hoft D.F., Stumpo D.J., Blackshear P.J., Liu J. Posttranscriptional regulation of IL-23 expression by IFN-gamma through tristetraprolin. J. Immunol. 2011, 186:6454-6464.
176. Al-Haj L., Blackshear P.J., Khabar K.S. Regulation of p21/CIP1/WAF-1 mediated cell-cycle arrest by RNase L and tristetraprolin, and involvement of AU-rich elements. Nucleic Acids Res. Sep 2012, 40(16):7739-7752.
177. Lee H.H., Yoon N.A., Vo M.T., Kim C.W., Woo J.M., Cha H.J., Cho Y.W., Lee B.J., Cho W.J., Park J.W. Tristetraprolin down-regulates IL-17 through mRNA destabilization. FEBS Lett. 2012, 586:41-46.
178. Mahat D.B., Brennan-Laun S.E., Fialcowitz-White E.J., Kishor A., Ross C.R., Pozharskaya T., Rawn J.D., Blackshear P.J., Hassel B.A., Wilson G.M. Coordinated expression of tristetraprolin post-transcriptionally attenuates mitogenic induction of the oncogenic Ser/Thr kinase Pim-1. PLoS One 2012, 7:e33194.
179. Novakovic D., Kuo A.C., Lin J.H., Koschinsky M.L., Boffa M.B. Identification of tristetraprolin as a factor that modulates the stability of the TAFI transcript through binding to the 3'-untranslated region. J. Thromb. Haemost. 2012, 10:887-894.
180. Ishmael F.T., Fang X., Galdiero M.R., Atasoy U., Rigby W.F., Gorospe M., Cheadle C., Stellato C. Role of the RNA-binding protein tristetraprolin in glucocorticoid-mediated gene regulation. J. Immunol. 2008, 180:8342-8353.
181. Emmons J., Townley-Tilson W.H., Deleault K.M., Skinner S.J., Gross R.H., Whitfield M.L., Brooks S.A. Identification of TTP mRNA targets in human dendritic cells reveals TTP as a critical regulator of dendritic cell maturation. RNA 2008, 14:888-902.
182. Bros M., Wiechmann N., Besche V., Art J., Pautz A., Grabbe S., Kleinert H., Reske-Kunz A.B. The RNA binding protein tristetraprolin influences the activation state of murine dendritic cells. Mol. Immunol. 2010, 47:1161-1170.
183. Lehner B., Sanderson C.M. A protein interaction framework for human mRNA degradation. Genome Res. 2004, 14:1315-1323.
184. Su Y.L., Wang S.C., Chiang P.Y., Lin N.Y., Shen Y.F., Chang G.D., Chang C.J. Tristetraprolin inhibits poly(A)-tail synthesis in nuclear mRNA that contains AU-rich elements by interacting with poly(A)-binding protein nuclear 1. PLoS One 2012, 7:e41313.
185. Kedar V.P., Darby M.K., Williams J.G., Blackshear P.J. Phosphorylation of human tristetraprolin in response to its interaction with the Cbl interacting protein CIN85. PLoS One 2010, 5:e9588.
186. Chang W.L., Tarn W.Y. A role for transportin in deposition of TTP to cytoplasmic RNA granules and mRNA decay. Nucleic Acids Res. 2009, 37:6600-6612.
187. Carman J.A., Nadler S.G. Direct association of tristetraprolin with the nucleoporin CAN/Nup214. Biochem. Biophys. Res. Commun. 2004, 315:445-449.
188. Rowlett R.M., Chrestensen C.A., Schroeder M.J., Harp M.G., Pelo J.W., Shabanowitz J., DeRose R., Hunt D.F., Sturgill T.W., Worthington M.T. Inhibition of tristetraprolin deadenylation by poly(A) binding protein. Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 295:G421-G430.
189. Chen G., Guo X., Lv F., Xu Y., Gao G. p72 DEAD box RNA helicase is required for optimal function of the zinc-finger antiviral protein. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:4352-4357.
190. Kedar V.P., Zucconi B.E., Wilson G.M., Blackshear P.J. Direct binding of specific AUF1 isoforms to tandem zinc finger domains of tristetraprolin (TTP) family proteins. J. Biol. Chem. 2012, 287:5459-5471.
191. Frasca D., Romero M., Landin A.M., Diaz A., Riley R.L., Blomberg B.B. Protein phosphatase 2A (PP2A) is increased in old murine B cells and mediates p38 MAPK/tristetraprolin dephosphorylation and E47 mRNA instability. Mech. Ageing Dev. 2010, 131:306-314.
192. Schichl Y.M., Resch U., Lemberger C.E., Stichlberger D., de Martin R. Novel phosphorylation-dependent ubiquitination of tristetraprolin by mitogen-activated protein kinase/extracellular signal-regulated kinase kinase kinase 1 (MEKK1) and tumor necrosis factor receptor-associated factor 2 (TRAF2). J. Biol. Chem. 2011, 286:38466-38477.
193. Papin J., Subramaniam S. Bioinformatics and cellular signaling. Curr. Opin. Biotechnol. 2004, 15:78-81.
194. Johnson B.A., Stehn J.R., Yaffe M.B., Blackwell T.K. Cytoplasmic localization of tristetraprolin involves 14-3-3-dependent and -independent mechanisms. J. Biol. Chem. 2002, 277:18029-18036.
195. Lin N.Y., Lin T.Y., Yang W.H., Wang S.C., Wang K.T., Su Y.L., Jiang Y.W., Chang G.D., Chang C.J. Differential expression and functional analysis of the tristetraprolin family during early differentiation of 3T3-L1 preadipocytes. Int. J. Biol. Sci. 2012, 8:761-777.
196. Twizere J.C., Kruys V., Lefebvre L., Vanderplasschen A., Collete D., Debacq C., Lai W.S., Jauniaux J.C., Bernstein L.R., Semmes O.J., Burny A., Blackshear P.J., Kettmann R., Willems L. Interaction of retroviral Tax oncoproteins with tristetraprolin and regulation of tumor necrosis factor-alpha expression. J. Natl. Cancer Inst. 2003, 95:1846-1859.
197. Rual J.F., Venkatesan K., Hao T., Hirozane-Kishikawa T., Dricot A., Li N., Berriz G.F., Gibbons F.D., Dreze M., Ayivi-Guedehoussou N., Klitgord N., Simon C., Boxem M., Milstein S., Rosenberg J., Goldberg D.S., Zhang L.V., Wong S.L., Franklin G., Li S., Albala J.S., Lim J., Fraughton C., Llamosas E., Cevik S., Bex C., Lamesch P., Sikorski R.S., Vandenhaute J., Zoghbi H.Y., Smolyar A., Bosak S., Sequerra R., Doucette-Stamm L., Cusick M.E., Hill D.E., Roth F.P., Vidal M. Towards a proteome-scale map of the human protein-protein interaction network. Nature 2005, 437:1173-1178.
198. Dintilhac A., Bernues J. HMGB1 interacts with many apparently unrelated proteins by recognizing short amino acid sequences. J. Biol. Chem. 2002, 277:7021-7028.
199. Ozgur S., Chekulaeva M., Stoecklin G. Human Pat1b connects deadenylation with mRNA decapping and controls the assembly of processing bodies. Mol. Cell. Biol. 2010, 30:4308-4323.